Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer

In FLAURA2, osimertinib monotherapy and combination with platinum-pemetrexed as first-line treatment for EGFR-mutated advanced NSCLC had non-clinically meaningful impacts on HRQoL in mildly symptomatic patients.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-03-09
DOI
https://doi.org/10.1158/1078-0432.ccr-25-3431
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Muna Albayaty, Gustavo Dix Junqueira Pinto, Jerry Tan Chun Bing, Shoichi Kuyama et al.
Clinical Cancer Research
Lung Cancer Treatments and Mutations
article

Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer

Muna Albayaty, Gustavo Dix Junqueira Pinto, Jerry Tan Chun Bing, Shoichi Kuyama, Terufumi Kato, Zhigang Han, Konstantin P Laktionov, Peter Mitchell, Lynne Poole, Rachel Lai, J Gray, Sang-We Kim, Chee Khoon Lee, Jialei Wang, Kunihiko Kobayashi, Neha P. Amin, Frances A. Shepherd, Juan Cundom
article en

Abstract

In FLAURA2, osimertinib monotherapy and combination with platinum-pemetrexed as first-line treatment for EGFR-mutated advanced NSCLC had non-clinically meaningful impacts on HRQoL in mildly symptomatic patients.

Clinical Cancer Research
AstraZeneca (United Kingdom) (GB), University Health Network (CA), Xinjiang Medical University (CN), Kanagawa Prefectural Hospital Organization (JP), Moffitt Cancer Center (US), University of Ulsan (KR), Russian Cancer Research Center NN Blokhin (RU), Hospital de Câncer de Barretos (BR), Fudan University Shanghai Cancer Center (CN), Tumor Hospital of Xinjiang Medical University (CN), Cebu Doctors' University (PH), Instituto de Diagnóstico e Investigaciones Metabólicas (AR), AstraZeneca (Netherlands) (NL), AstraZeneca (Singapore) (SG), St George Hospital (AU), AstraZeneca (Japan) (JP), Iwakuni Medical Center (JP), AstraZeneca (Poland) (PL), St. George Hospital (IN), Olivia Newton-John Cancer Wellness & Research Centre (AU), Saitama Medical University (JP)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Gilead Sciences, International Association for the Study of Lung Cancer, American Society of Clinical Oncology, Regeneron Pharmaceuticals, Merck KGaA, Novocure, BeiGene, Yuhan, Chugai Pharmaceutical, Daiichi Sankyo Europe
Good health and well-being
Openalex Percentile: Top 28%
Lung Cancer Treatments and Mutations
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.